On May 13, 2025, UBS analyst Trung Huynh maintained a Buy rating for Jasper Therapeutics (JSPR, Financial), indicating continued confidence in the company's potential despite adjusting the price target. The updated price target for JSPR has been lowered from $38.00 to $33.00 USD.
The adjustment reflects a decrease of 13.16% from the prior price target. Despite this change, the maintained Buy rating suggests that UBS still sees significant growth potential for Jasper Therapeutics (JSPR, Financial) at the current valuation.
Investors in Jasper Therapeutics (JSPR, Financial) will be monitoring the company's performance to determine if it can meet or exceed the revised price target of $33.00 USD set by UBS.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $49.75 with a high estimate of $80.00 and a low estimate of $15.00. The average target implies an upside of 936.46% from the current price of $4.80. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
